Adamas announces gocovri presentations at the upcoming international parkinson and movement disorder society's (mds) congress

Emeryville, calif.--(business wire)--adamas pharmaceuticals, inc. (nasdaq: adms), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced five posters will be presented at the international parkinson and movement disorder society (mds) virtual congress, taking place september 17 – 22, 2021. the poster presentations will focus on gocovri® (amantadine) extended-release capsules, the first and only fd
ADMS Ratings Summary
ADMS Quant Ranking